1. Home
  2. MBUU vs ABUS Comparison

MBUU vs ABUS Comparison

Compare MBUU & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Malibu Boats Inc.

MBUU

Malibu Boats Inc.

HOLD

Current Price

$29.70

Market Cap

554.5M

Sector

Industrials

ML Signal

HOLD

Logo Arbutus Biopharma Corporation

ABUS

Arbutus Biopharma Corporation

HOLD

Current Price

$4.75

Market Cap

848.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MBUU
ABUS
Founded
1982
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Marine Transportation
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
554.5M
848.1M
IPO Year
2014
N/A

Fundamental Metrics

Financial Performance
Metric
MBUU
ABUS
Price
$29.70
$4.75
Analyst Decision
Hold
Strong Buy
Analyst Count
8
2
Target Price
$33.57
$5.00
AVG Volume (30 Days)
270.9K
1.1M
Earning Date
01-29-2026
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.98
N/A
Revenue
$830,714,000.00
$14,606,000.00
Revenue This Year
N/A
$125.30
Revenue Next Year
$7.03
N/A
P/E Ratio
$30.05
N/A
Revenue Growth
11.54
116.64
52 Week Low
$24.07
$2.71
52 Week High
$44.62
$5.10

Technical Indicators

Market Signals
Indicator
MBUU
ABUS
Relative Strength Index (RSI) 58.35 60.87
Support Level $28.70 $4.43
Resistance Level $30.41 $4.63
Average True Range (ATR) 1.30 0.19
MACD 0.42 0.04
Stochastic Oscillator 84.75 89.66

Price Performance

Historical Comparison
MBUU
ABUS

About MBUU Malibu Boats Inc.

Malibu Boats is a designer and manufacturer of power boats in the United States. It is a market leader in performance sport boats, sold under its Malibu and Axis brands. It acquired Cobalt Boats, a producer of sterndrive boats, in 2017, and Pursuit Boats, which makes high end offshore and outboard motorboats in 2018. In 2021, it purchased Maverick Boat Group, a seller of flat fishing boats, with exposure to bay, dual console, and center console boats. Malibu has also expanded into boat trailers and accessories, and in 2020, began producing its own engines for its performance sport boats.

About ABUS Arbutus Biopharma Corporation

Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.

Share on Social Networks: